|
| 产地 | 国产 |
| 品牌 | Solarbio |
| 货号 | IH0150 |
| 用途 | 抑制剂 |
| 包装规格 | 50mg |
| CAS编号 | 127-07-1 |
| 纯度 | 98% |
| 是否进口 | 否 |
| CAS | 127-07-1 |
| 中文名称 | 羟基脲 |
| 英文名称 | Hydroxyurea |
| 别名 | 羟基尿素; Droxia; Oxyurea |
| 纯度 | HPLC≥98% |
| 分子式 | CH4N2O2 |
| 分子量 | 76.05 |
| 外观（性状） | White to off-white Solid |
| 储存条件 | Powder : 2-8℃, 2 years; In solvent(母液): -20℃, 1 month; -80℃, 6 months |
| 溶解性 | Soluble in Water/DMSO |
| EC | EINECS 204-821-7 |
| MDL | MFCD00007943 |
| InChIKey | VSNHCAURESNICA-UHFFFAOYSA-N |
| InChI | InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) |
| PubChem CID | 3657 |
| SMILES | O=C(N)NO |
| 描述 | Hydroxyurea通过抑制核糖核苷酸还原酶抑制DNA合成的细胞凋亡诱导剂。(Hydroxyurea is an apoptosis inducer that inhibits DNA synthesis by inhibiting ribonucleotide reductase.) |
| 靶点 | DNA/RNA Synthesis |
| 通路 | Cell Cycle;DNA Damage/DNA Repair |
| 生物活性 | Hydroxyurea是通过抑制核糖核苷酸还原酶抑制DNA合成的细胞凋亡诱导剂。[1-4] |
|
|
|
| 数据来源文献 |
[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. |
| 规格 | 50mg 100mg 10mM*1mL (in DMSO) |
| 单位 | 瓶 |
